Ildong Pharmaceutical Group to Focus on Securing New Growth Engines This Year

Ildong Pharmaceutical Group held its 2026 opening ceremony on the 5th at its headquarters in Seocho-gu, Seoul, and at major business sites nationwide, with executives and employees of the holding company and affiliates in attendance.

Ildong Pharmaceutical Group has once again set its management policy for this year as 'ID 4.0, Creating Competitive Advantage and Results,' following last year. The group established two detailed indicators: △ generating sales and profit performance, and △ securing new growth engines and establishing a sustainable business system.

Ildong Pharmaceutical Group held the 2026 New Year's Opening Ceremony on the 5th at its headquarters in Seocho-gu, Seoul, and major business sites nationwide, with executives and employees of the holding company and its affiliates in attendance. Ildong Pharmaceutical

The group's strategy is to enhance profitability by achieving targets in its core business areas and improving productivity through cost innovation, with Ildong Pharmaceutical as the focal point. The group also aims to establish a virtuous cycle by reorganizing its portfolio and discovering new business models.

In addition, the group plans to leverage its company-wide capabilities to drive results in global business development, actively pursuing overseas licensing-out and open innovation based on its new drug R&D activities and pipeline assets.

Park Dae-chang, Chairman of the holding company Ildong Holdings, expressed his gratitude to executives and employees for faithfully carrying out their duties over the past year in his New Year's address, and offered words of encouragement and requests as the new year begins.

Chairman Park emphasized, "Despite challenging circumstances last year, we strengthened our business and cost structures, diversified our marketing, launched new products, and thereby reinforced our sales base and improved profitability."

He also reflected, "In the field of research and development, we made visible progress in major new drug projects such as the GLP-1 RA obesity treatment, P-CAB peptic ulcer treatment, and new anticancer drugs."

In particular, he added, "For the oral obesity drug candidate 'ID110521156,' we demonstrated superior efficacy and safety compared to competitors in Phase 1 clinical trials, drawing attention from the market and raising expectations for commercialization, including technology transfer."

Chairman Park stressed, "This year, the pharmaceutical industry is expected to face major changes in the market environment, such as drug price reductions. To respond to these challenges, achieving the given targets must be the top priority, and we must make every effort to improve the group's overall structure and secure new growth engines, with Ildong Pharmaceutical at the center."